Furthermore, the commonly prescribed lipid-lowering atorvastatin had shown to diminish the PD-L1 induction by IFNγ alone or IFNγ/TNFα combination, implying that the use of atorvastatin might be helpful in developing therapeutic strategies to counter the immune evasion in cancers. The gene discussed is IFNG; the disease is cancer.